Board Committees

Chair
Member
Audit Committee Position

Geoffrey E. Harris

Geoffrey E. Harris joined our Board of Directors on July 30, 2015.  Mr. Harris is a portfolio manager and managing partner at c7 Advisors, a money management and healthcare advisory firm focused on small-to-middle market healthcare companies.  Prior to his position with c7 Advisors, Mr. Harris served as Managing Director and co-head of the Cantor Fitzgerald Healthcare Investment Banking Group from 2011 to 2014, and was a Healthcare Investment Banker with Gleacher & Company from 2009 to 2011.  Mr. Harris has over thirty years combined experience as a healthcare analyst and portfolio manager for biotechnology, life sciences and healthcare services companies.  Mr. Harris graduated from MIT's Sloan School of Management with an MS in Finance Management.  Mr. Harris serves as a director on the boards of Cancer Genetics, Inc. (NASDAQ:  CGIX) a molecular diagnostics company, American Care Source, Inc. (NASDAQ: ANCI) a healthcare services company, and two privately held companies, ConnectRN a technology enabled healthcare services company and PointRight, a healthcare data analytics company.  Mr. Harris also serves on the Audit Committee of Cancer Genetics, Inc.  Mr. Harris was selected to serve on our Board of Directors for his significant healthcare, finance and transactional experience.  Furthermore, his financial, analytical and audit committee experience make him well suited to Chair our Audit Committee.

Chair

Michal Votruba

Michal Votruba joined our board on July 30, 2015.  Since 2013, Mr. Votruba has been the Director of the Gradus/RSJ Life Sciences Fund, the largest dedicated fund in Central Europe with a portfolio of companies in Europe and the United States.  Since 2010, he has served as a member of the board of PrimeCell Therapeutics a.s. as the Director of Global Business Development overseeing the expansion of the largest regenerative medicine company operating in Central Europe.  In 2009, the Czech Academy of Sciences solicited Mr. Votruba's expertise for the first successful privatization project of the Institute of Experimental Medicine in Prague:  the newly created protocol established a precedent for future privatization projects in the Czech Republic.  Mr. Votruba graduated as a Clinical Psychiatrist from the Medical Faculty of Charles University in Prague in 1989.  Shortly thereafter, he emigrated from Czechoslovakia and developed his professional career in Canada and the USA.  Since 2005, Mr. Votruba combined his theoretical and clinical experience in the field of Competitive Intelligence serving the global pharmaceutical industry for eight years as an industry analyst advising senior leaders of companies including Amgen, Novartis, Eli Lilly, Allergan, EMD, Serono and Sanofi.  Mr. Votruba brings valuable expertise to the Board as a clinical psychiatrist and broad experience in the international marketing of innovative medical technologies.

Member

John Pappajohn

John Pappajohn joined our board of directors on August 26, 2009.  Since 1969, Mr. Pappajohn has been the President and sole owner of Pappajohn Capital Resources, a venture capital firm, and President and sole owner of Equity Dynamics, Inc., a financial consulting firm, both located in Des Moines, Iowa.  Since 1994 he has served as a director on the board of public company American CareSource Holdings, Inc., Dallas, TX.  During the past five years he has served on the boards of public companies Conmed Healthcare Management, Inc., PharmAthene, Inc. and Spectrascience, Inc. Mr. Pappajohn also currently serves as Chairman of the Board of Cancer Genetics, Inc. Mr. Pappajohn was chosen to serve as a director of our company because of his unparalleled experience serving as a director of more than 40 companies and the substantial insight he has gained into the life sciences and healthcare industries by actively investing in the industries for more than 40 years, and by founding and supporting several public healthcare companies. 

Member

Audit Committee Charter

Download
Governance and Nominations Committee Position

Michal Votruba

Michal Votruba joined our board on July 30, 2015.  Since 2013, Mr. Votruba has been the Director of the Gradus/RSJ Life Sciences Fund, the largest dedicated fund in Central Europe with a portfolio of companies in Europe and the United States.  Since 2010, he has served as a member of the board of PrimeCell Therapeutics a.s. as the Director of Global Business Development overseeing the expansion of the largest regenerative medicine company operating in Central Europe.  In 2009, the Czech Academy of Sciences solicited Mr. Votruba's expertise for the first successful privatization project of the Institute of Experimental Medicine in Prague:  the newly created protocol established a precedent for future privatization projects in the Czech Republic.  Mr. Votruba graduated as a Clinical Psychiatrist from the Medical Faculty of Charles University in Prague in 1989.  Shortly thereafter, he emigrated from Czechoslovakia and developed his professional career in Canada and the USA.  Since 2005, Mr. Votruba combined his theoretical and clinical experience in the field of Competitive Intelligence serving the global pharmaceutical industry for eight years as an industry analyst advising senior leaders of companies including Amgen, Novartis, Eli Lilly, Allergan, EMD, Serono and Sanofi.  Mr. Votruba brings valuable expertise to the Board as a clinical psychiatrist and broad experience in the international marketing of innovative medical technologies.

Chair

John Pappajohn

John Pappajohn joined our board of directors on August 26, 2009.  Since 1969, Mr. Pappajohn has been the President and sole owner of Pappajohn Capital Resources, a venture capital firm, and President and sole owner of Equity Dynamics, Inc., a financial consulting firm, both located in Des Moines, Iowa.  Since 1994 he has served as a director on the board of public company American CareSource Holdings, Inc., Dallas, TX.  During the past five years he has served on the boards of public companies Conmed Healthcare Management, Inc., PharmAthene, Inc. and Spectrascience, Inc. Mr. Pappajohn also currently serves as Chairman of the Board of Cancer Genetics, Inc. Mr. Pappajohn was chosen to serve as a director of our company because of his unparalleled experience serving as a director of more than 40 companies and the substantial insight he has gained into the life sciences and healthcare industries by actively investing in the industries for more than 40 years, and by founding and supporting several public healthcare companies. 

Member

Geoffrey E. Harris

Geoffrey E. Harris joined our Board of Directors on July 30, 2015.  Mr. Harris is a portfolio manager and managing partner at c7 Advisors, a money management and healthcare advisory firm focused on small-to-middle market healthcare companies.  Prior to his position with c7 Advisors, Mr. Harris served as Managing Director and co-head of the Cantor Fitzgerald Healthcare Investment Banking Group from 2011 to 2014, and was a Healthcare Investment Banker with Gleacher & Company from 2009 to 2011.  Mr. Harris has over thirty years combined experience as a healthcare analyst and portfolio manager for biotechnology, life sciences and healthcare services companies.  Mr. Harris graduated from MIT's Sloan School of Management with an MS in Finance Management.  Mr. Harris serves as a director on the boards of Cancer Genetics, Inc. (NASDAQ:  CGIX) a molecular diagnostics company, American Care Source, Inc. (NASDAQ: ANCI) a healthcare services company, and two privately held companies, ConnectRN a technology enabled healthcare services company and PointRight, a healthcare data analytics company.  Mr. Harris also serves on the Audit Committee of Cancer Genetics, Inc.  Mr. Harris was selected to serve on our Board of Directors for his significant healthcare, finance and transactional experience.  Furthermore, his financial, analytical and audit committee experience make him well suited to Chair our Audit Committee.

Member

Governance and Nominations Committee Charter

Download
Compensation Committee Position

John Pappajohn

John Pappajohn joined our board of directors on August 26, 2009.  Since 1969, Mr. Pappajohn has been the President and sole owner of Pappajohn Capital Resources, a venture capital firm, and President and sole owner of Equity Dynamics, Inc., a financial consulting firm, both located in Des Moines, Iowa.  Since 1994 he has served as a director on the board of public company American CareSource Holdings, Inc., Dallas, TX.  During the past five years he has served on the boards of public companies Conmed Healthcare Management, Inc., PharmAthene, Inc. and Spectrascience, Inc. Mr. Pappajohn also currently serves as Chairman of the Board of Cancer Genetics, Inc. Mr. Pappajohn was chosen to serve as a director of our company because of his unparalleled experience serving as a director of more than 40 companies and the substantial insight he has gained into the life sciences and healthcare industries by actively investing in the industries for more than 40 years, and by founding and supporting several public healthcare companies. 

Chair

Michal Votruba

Michal Votruba joined our board on July 30, 2015.  Since 2013, Mr. Votruba has been the Director of the Gradus/RSJ Life Sciences Fund, the largest dedicated fund in Central Europe with a portfolio of companies in Europe and the United States.  Since 2010, he has served as a member of the board of PrimeCell Therapeutics a.s. as the Director of Global Business Development overseeing the expansion of the largest regenerative medicine company operating in Central Europe.  In 2009, the Czech Academy of Sciences solicited Mr. Votruba's expertise for the first successful privatization project of the Institute of Experimental Medicine in Prague:  the newly created protocol established a precedent for future privatization projects in the Czech Republic.  Mr. Votruba graduated as a Clinical Psychiatrist from the Medical Faculty of Charles University in Prague in 1989.  Shortly thereafter, he emigrated from Czechoslovakia and developed his professional career in Canada and the USA.  Since 2005, Mr. Votruba combined his theoretical and clinical experience in the field of Competitive Intelligence serving the global pharmaceutical industry for eight years as an industry analyst advising senior leaders of companies including Amgen, Novartis, Eli Lilly, Allergan, EMD, Serono and Sanofi.  Mr. Votruba brings valuable expertise to the Board as a clinical psychiatrist and broad experience in the international marketing of innovative medical technologies.

Member

Geoffrey E. Harris

Geoffrey E. Harris joined our Board of Directors on July 30, 2015.  Mr. Harris is a portfolio manager and managing partner at c7 Advisors, a money management and healthcare advisory firm focused on small-to-middle market healthcare companies.  Prior to his position with c7 Advisors, Mr. Harris served as Managing Director and co-head of the Cantor Fitzgerald Healthcare Investment Banking Group from 2011 to 2014, and was a Healthcare Investment Banker with Gleacher & Company from 2009 to 2011.  Mr. Harris has over thirty years combined experience as a healthcare analyst and portfolio manager for biotechnology, life sciences and healthcare services companies.  Mr. Harris graduated from MIT's Sloan School of Management with an MS in Finance Management.  Mr. Harris serves as a director on the boards of Cancer Genetics, Inc. (NASDAQ:  CGIX) a molecular diagnostics company, American Care Source, Inc. (NASDAQ: ANCI) a healthcare services company, and two privately held companies, ConnectRN a technology enabled healthcare services company and PointRight, a healthcare data analytics company.  Mr. Harris also serves on the Audit Committee of Cancer Genetics, Inc.  Mr. Harris was selected to serve on our Board of Directors for his significant healthcare, finance and transactional experience.  Furthermore, his financial, analytical and audit committee experience make him well suited to Chair our Audit Committee.

Member

Compensation Committee Charter

Download

Geoffrey E. Harris

Geoffrey E. Harris joined our Board of Directors on July 30, 2015.  Mr. Harris is a portfolio manager and managing partner at c7 Advisors, a money management and healthcare advisory firm focused on small-to-middle market healthcare companies.  Prior to his position with c7 Advisors, Mr. Harris served as Managing Director and co-head of the Cantor Fitzgerald Healthcare Investment Banking Group from 2011 to 2014, and was a Healthcare Investment Banker with Gleacher & Company from 2009 to 2011.  Mr. Harris has over thirty years combined experience as a healthcare analyst and portfolio manager for biotechnology, life sciences and healthcare services companies.  Mr. Harris graduated from MIT's Sloan School of Management with an MS in Finance Management.  Mr. Harris serves as a director on the boards of Cancer Genetics, Inc. (NASDAQ:  CGIX) a molecular diagnostics company, American Care Source, Inc. (NASDAQ: ANCI) a healthcare services company, and two privately held companies, ConnectRN a technology enabled healthcare services company and PointRight, a healthcare data analytics company.  Mr. Harris also serves on the Audit Committee of Cancer Genetics, Inc.  Mr. Harris was selected to serve on our Board of Directors for his significant healthcare, finance and transactional experience.  Furthermore, his financial, analytical and audit committee experience make him well suited to Chair our Audit Committee.

Michal Votruba

Michal Votruba joined our board on July 30, 2015.  Since 2013, Mr. Votruba has been the Director of the Gradus/RSJ Life Sciences Fund, the largest dedicated fund in Central Europe with a portfolio of companies in Europe and the United States.  Since 2010, he has served as a member of the board of PrimeCell Therapeutics a.s. as the Director of Global Business Development overseeing the expansion of the largest regenerative medicine company operating in Central Europe.  In 2009, the Czech Academy of Sciences solicited Mr. Votruba's expertise for the first successful privatization project of the Institute of Experimental Medicine in Prague:  the newly created protocol established a precedent for future privatization projects in the Czech Republic.  Mr. Votruba graduated as a Clinical Psychiatrist from the Medical Faculty of Charles University in Prague in 1989.  Shortly thereafter, he emigrated from Czechoslovakia and developed his professional career in Canada and the USA.  Since 2005, Mr. Votruba combined his theoretical and clinical experience in the field of Competitive Intelligence serving the global pharmaceutical industry for eight years as an industry analyst advising senior leaders of companies including Amgen, Novartis, Eli Lilly, Allergan, EMD, Serono and Sanofi.  Mr. Votruba brings valuable expertise to the Board as a clinical psychiatrist and broad experience in the international marketing of innovative medical technologies.

John Pappajohn

John Pappajohn joined our board of directors on August 26, 2009.  Since 1969, Mr. Pappajohn has been the President and sole owner of Pappajohn Capital Resources, a venture capital firm, and President and sole owner of Equity Dynamics, Inc., a financial consulting firm, both located in Des Moines, Iowa.  Since 1994 he has served as a director on the board of public company American CareSource Holdings, Inc., Dallas, TX.  During the past five years he has served on the boards of public companies Conmed Healthcare Management, Inc., PharmAthene, Inc. and Spectrascience, Inc. Mr. Pappajohn also currently serves as Chairman of the Board of Cancer Genetics, Inc. Mr. Pappajohn was chosen to serve as a director of our company because of his unparalleled experience serving as a director of more than 40 companies and the substantial insight he has gained into the life sciences and healthcare industries by actively investing in the industries for more than 40 years, and by founding and supporting several public healthcare companies. 

Michal Votruba

Michal Votruba joined our board on July 30, 2015.  Since 2013, Mr. Votruba has been the Director of the Gradus/RSJ Life Sciences Fund, the largest dedicated fund in Central Europe with a portfolio of companies in Europe and the United States.  Since 2010, he has served as a member of the board of PrimeCell Therapeutics a.s. as the Director of Global Business Development overseeing the expansion of the largest regenerative medicine company operating in Central Europe.  In 2009, the Czech Academy of Sciences solicited Mr. Votruba's expertise for the first successful privatization project of the Institute of Experimental Medicine in Prague:  the newly created protocol established a precedent for future privatization projects in the Czech Republic.  Mr. Votruba graduated as a Clinical Psychiatrist from the Medical Faculty of Charles University in Prague in 1989.  Shortly thereafter, he emigrated from Czechoslovakia and developed his professional career in Canada and the USA.  Since 2005, Mr. Votruba combined his theoretical and clinical experience in the field of Competitive Intelligence serving the global pharmaceutical industry for eight years as an industry analyst advising senior leaders of companies including Amgen, Novartis, Eli Lilly, Allergan, EMD, Serono and Sanofi.  Mr. Votruba brings valuable expertise to the Board as a clinical psychiatrist and broad experience in the international marketing of innovative medical technologies.

John Pappajohn

John Pappajohn joined our board of directors on August 26, 2009.  Since 1969, Mr. Pappajohn has been the President and sole owner of Pappajohn Capital Resources, a venture capital firm, and President and sole owner of Equity Dynamics, Inc., a financial consulting firm, both located in Des Moines, Iowa.  Since 1994 he has served as a director on the board of public company American CareSource Holdings, Inc., Dallas, TX.  During the past five years he has served on the boards of public companies Conmed Healthcare Management, Inc., PharmAthene, Inc. and Spectrascience, Inc. Mr. Pappajohn also currently serves as Chairman of the Board of Cancer Genetics, Inc. Mr. Pappajohn was chosen to serve as a director of our company because of his unparalleled experience serving as a director of more than 40 companies and the substantial insight he has gained into the life sciences and healthcare industries by actively investing in the industries for more than 40 years, and by founding and supporting several public healthcare companies. 

Geoffrey E. Harris

Geoffrey E. Harris joined our Board of Directors on July 30, 2015.  Mr. Harris is a portfolio manager and managing partner at c7 Advisors, a money management and healthcare advisory firm focused on small-to-middle market healthcare companies.  Prior to his position with c7 Advisors, Mr. Harris served as Managing Director and co-head of the Cantor Fitzgerald Healthcare Investment Banking Group from 2011 to 2014, and was a Healthcare Investment Banker with Gleacher & Company from 2009 to 2011.  Mr. Harris has over thirty years combined experience as a healthcare analyst and portfolio manager for biotechnology, life sciences and healthcare services companies.  Mr. Harris graduated from MIT's Sloan School of Management with an MS in Finance Management.  Mr. Harris serves as a director on the boards of Cancer Genetics, Inc. (NASDAQ:  CGIX) a molecular diagnostics company, American Care Source, Inc. (NASDAQ: ANCI) a healthcare services company, and two privately held companies, ConnectRN a technology enabled healthcare services company and PointRight, a healthcare data analytics company.  Mr. Harris also serves on the Audit Committee of Cancer Genetics, Inc.  Mr. Harris was selected to serve on our Board of Directors for his significant healthcare, finance and transactional experience.  Furthermore, his financial, analytical and audit committee experience make him well suited to Chair our Audit Committee.

John Pappajohn

John Pappajohn joined our board of directors on August 26, 2009.  Since 1969, Mr. Pappajohn has been the President and sole owner of Pappajohn Capital Resources, a venture capital firm, and President and sole owner of Equity Dynamics, Inc., a financial consulting firm, both located in Des Moines, Iowa.  Since 1994 he has served as a director on the board of public company American CareSource Holdings, Inc., Dallas, TX.  During the past five years he has served on the boards of public companies Conmed Healthcare Management, Inc., PharmAthene, Inc. and Spectrascience, Inc. Mr. Pappajohn also currently serves as Chairman of the Board of Cancer Genetics, Inc. Mr. Pappajohn was chosen to serve as a director of our company because of his unparalleled experience serving as a director of more than 40 companies and the substantial insight he has gained into the life sciences and healthcare industries by actively investing in the industries for more than 40 years, and by founding and supporting several public healthcare companies. 

Michal Votruba

Michal Votruba joined our board on July 30, 2015.  Since 2013, Mr. Votruba has been the Director of the Gradus/RSJ Life Sciences Fund, the largest dedicated fund in Central Europe with a portfolio of companies in Europe and the United States.  Since 2010, he has served as a member of the board of PrimeCell Therapeutics a.s. as the Director of Global Business Development overseeing the expansion of the largest regenerative medicine company operating in Central Europe.  In 2009, the Czech Academy of Sciences solicited Mr. Votruba's expertise for the first successful privatization project of the Institute of Experimental Medicine in Prague:  the newly created protocol established a precedent for future privatization projects in the Czech Republic.  Mr. Votruba graduated as a Clinical Psychiatrist from the Medical Faculty of Charles University in Prague in 1989.  Shortly thereafter, he emigrated from Czechoslovakia and developed his professional career in Canada and the USA.  Since 2005, Mr. Votruba combined his theoretical and clinical experience in the field of Competitive Intelligence serving the global pharmaceutical industry for eight years as an industry analyst advising senior leaders of companies including Amgen, Novartis, Eli Lilly, Allergan, EMD, Serono and Sanofi.  Mr. Votruba brings valuable expertise to the Board as a clinical psychiatrist and broad experience in the international marketing of innovative medical technologies.

Geoffrey E. Harris

Geoffrey E. Harris joined our Board of Directors on July 30, 2015.  Mr. Harris is a portfolio manager and managing partner at c7 Advisors, a money management and healthcare advisory firm focused on small-to-middle market healthcare companies.  Prior to his position with c7 Advisors, Mr. Harris served as Managing Director and co-head of the Cantor Fitzgerald Healthcare Investment Banking Group from 2011 to 2014, and was a Healthcare Investment Banker with Gleacher & Company from 2009 to 2011.  Mr. Harris has over thirty years combined experience as a healthcare analyst and portfolio manager for biotechnology, life sciences and healthcare services companies.  Mr. Harris graduated from MIT's Sloan School of Management with an MS in Finance Management.  Mr. Harris serves as a director on the boards of Cancer Genetics, Inc. (NASDAQ:  CGIX) a molecular diagnostics company, American Care Source, Inc. (NASDAQ: ANCI) a healthcare services company, and two privately held companies, ConnectRN a technology enabled healthcare services company and PointRight, a healthcare data analytics company.  Mr. Harris also serves on the Audit Committee of Cancer Genetics, Inc.  Mr. Harris was selected to serve on our Board of Directors for his significant healthcare, finance and transactional experience.  Furthermore, his financial, analytical and audit committee experience make him well suited to Chair our Audit Committee.